Molecular pathways like PI3K/AKT/mTOR, activated in obese patients due to high circulating levels of IGF1, could be a potential therapeutic target in bladder cancer patients with high BMI (46). This evidence concerns the gene AKT1 and urinary bladder carcinoma.